Drug Trial Radar · NCT00542997
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
Last checked: Nov 19, 2026Latest source record: Sep 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Sep 2007
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Oct 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
Conditions
- Common Variable Immunodeficiency
- X-linked Agammaglobulinemia
- Autosomal Recessive Agammaglobulinemia
Interventions
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)Biological
IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Serum IgG Trough LevelsTime frame: Up to 6 months prior to first IgPro20 treatment (Pre-study treatment) and Week 12 to 17 (IgPro20 treatment)
Locations
19 sites in 9 countries. Site status is shown where the registry gives one.
Study site
Paris, France
Study site
Berlin, Germany
Study site
Düsseldorf, Germany
Study site
Freiburg im Breisgau, Germany
Study site
Hanover, Germany
Study site
Leipzig, Germany
Study site
Mainz, Germany
Study site
Munich, Germany
Study site
Brescia, Italy
Study site
Warsaw, Poland
Study site
Bucharest, Romania
Study site
Cluj-Napoca, Romania
Study site
Timișoara, Romania
Study site
Barcelona, Spain
Study site
Seville, Spain
Study site
Gothenburg, Sweden
Study site
Bern, Switzerland
Study site
Cardiff, United Kingdom
Study site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.